Endocannabinoids were first defined in 1995 as 'endogenous substances capable of binding to and functionally activating the cannabinoid receptors'. To date, two well-established endocannabinoids, N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), as well as a few other putative ligands, all derived from long-chain polyunsaturated fatty acids, have been identified in animal tissues. The biosynthetic and metabolic pathways for anandamide and 2-AG have been elucidated, and most of the enzymes therein involved have been cloned. We now know that CB 1 receptors, and endocannabinoids in tissue concentrations sufficient to activate them, are more widely distributed than originally thought, and are found in brain and peripheral organs involved in the control of energy intake and processing, including the hypothalamus, nucleus accumbens, brainstem, vagus nerve, gastrointestinal tract, adipose tissue and liver. Endocannabinoid biosynthetic and inactivating pathways are under the regulation of neuropeptides and hormones involved in energy homeostasis, and endocannabinoid levels are directly affected by the diet. Endocannabinoids, in turn, regulate the expression and action of mediators involved in nutrient intake and processing. These cross-talks are at the basis of the proposed role of endocannabinoid signalling in the control of food intake, from invertebrates to lower vertebrates and mammals, and their perturbation appears to contribute to the development of eating disorders. and CB 2 receptors share very little homology, thus pointing to a very early separation of the two encoding genes during animal evolution. Indeed, the only cannabinoid receptor ortholog fully sequenced in an invertebrate species, the sea squirt Ciona intestinalis (chordata), exhibits low homology with both mammalian subtypes. 4 Orthologs of CB 1 receptors have been found so far in lower vertebrates, including fish, amphibians and birds. 4 Clearly, cannabinoid receptors have not been selected by millions of years of evolution to be activated by D 9 -THC. It is now known that these receptors serve as targets for endogenous compounds of lipophilic nature, the endocannabinoids (Figure 1 ). The two best studied endocannabinoids are anandamide (arachidonoylethanolamide) 5 and 2-arachidonoylglycerol. 6, 7 The activation by these compounds of CB 1 receptors expressed in presynaptic neurons results in inhibition of both excitatory and inhibitory neurotransmitter release in various brain areas, including those involved in food intake, 8, 9 often with the subsequent establishment of both short-and long-term forms of neuronal plasticity. 10 In fact, endocannabinoids are biosynthesised 'de novo' and 'on demand' (i.e. only when and where needed) within the framework of phospholipid metabolic reactions, to be immediately released from the cell in order to activate their targets, and then rapidly removed from the extracellular space by rapid and selective uptake into the cell followed by
The endocannabinoid system and its distribution
The cannabinoid CB 1 receptor, 1 one of the most abundant Gprotein-coupled receptors in the central nervous system, is thought to be responsible for the majority of the 'central' actions of D
9
-tetrahydrocannabinol (D 9 -THC). D
-THC is the major psychoactive component of Cannabis sativa and marijuana, 2 and it also activates cannabinoid CB 2 receptors, which, like CB 1 receptors, are coupled to G-proteins of the G i/o family, but, unlike their cognate receptors, are poorly expressed in the brain under physiological conditions, and are almost uniquely found in immune tissues and cells. 3 CB 1 and CB 2 receptors share very little homology, thus pointing to a very early separation of the two encoding genes during animal evolution. Indeed, the only cannabinoid receptor ortholog fully sequenced in an invertebrate species, the sea squirt Ciona intestinalis (chordata), exhibits low homology with both mammalian subtypes. 4 Orthologs of CB 1 receptors have been found so far in lower vertebrates, including fish, amphibians and birds. 4 Clearly, cannabinoid receptors have not been selected by millions of years of evolution to be activated by D 9 -THC. It is now known that these receptors serve as targets for endogenous compounds of lipophilic nature, the endocannabinoids ( Figure 1 ). The two best studied endocannabinoids are anandamide (arachidonoylethanolamide) 5 and 2-arachidonoylglycerol. 6, 7 The activation by these compounds of CB 1 receptors expressed in presynaptic neurons results in inhibition of both excitatory and inhibitory neurotransmitter release in various brain areas, including those involved in food intake, 8, 9 often with the subsequent establishment of both short-and long-term forms of neuronal plasticity. 10 In fact, endocannabinoids are biosynthesised 'de novo' and 'on demand' (i.e. only when and where needed) within the framework of phospholipid metabolic reactions, to be immediately released from the cell in order to activate their targets, and then rapidly removed from the extracellular space by rapid and selective uptake into the cell followed by enzymatic hydrolysis. 11 The cannabinoid receptors, the endocannabinoids, and the proteins for their biosynthesis and degradation constitute the endocannabinoid system.
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Several enzymes catalysing either the biosynthesis or the degradation of the two best-studied endocannabinoids have been identified and cloned to date (Figure 2 ). First the 'fatty acid amide hydrolase' (FAAH), which catalyses the hydrolysis of anandamide and 2-AG, was cloned from rat liver in 1996 12 and then from several other species. Subsequently, it was recognized that a previously cloned enzyme, the monoacylglycerol lipase (MAGL), played a key role, probably more important than FAAH, in the enzymatic hydrolysis of 2-AG. 13 Finally, the enzymes responsible for the last step of anandamide and 2-AG biosynthetic pathways, the N-acyl-phosphatidyl-ethanolamine-selective phospholipase D (NAPE-PLD) and the sn-1 selective diacylglycerol lipases (DAGLa and b), respectively, were cloned. 14, 15 All these proteins are hydrolytic enzymes of the Ser hydrolase family, except for the NAPE-PLD, which belongs to the zincmetalloproteinase family. Another common feature of these enzymes is their lack of selectivity for one particular member of the families of their substrates. In fact, NAPE-PLD recognizes several other N-acyl-phosphatidyl-ethanolamines, FAAH catalyses the hydrolysis of both long-chain N-acylethanolamines (NAEs) and primary amides, the DAGLs accept as substrates also DAGs with 2-acyl chains different from arachidonate, and the MAGL catalyses the hydrolysis of both sn-1 and 2-mono-acylglycerols (MAGs) with at least one double bond on the fatty acyl moiety. Yet another common property of these five enzymes is that, although their exact subcellular localization has not been fully understood yet, they seem to be at least in part located on cell membranes, where also their hydrophobic substrates are most likely to be partitioned. Thus, the NAPE-PLD and FAAH are found in intracellular membranes, whereas the DAGLs are restricted to the plasma membrane, and the MAGL is present in both cytosolic fractions and microsomal membranes. Furthermore, while FAAH and the DAGLs are postsynaptic enzymes in the adult brain, the MAGL is located presynaptically. This different cellular and subcellular compartmentalization of the biosynthetic and degradative enzymes of the two major endocannabinoids indicates different functions for anandamide and 2-AG, as suggested, for example, for short and long-term synaptic plasticity. 16 Finally, while the activity of the biosynthetic enzymes is stimulated by increased concentration of intracellular Ca 2 þ , resulting from neuronal depolarisation or intracellular Ca 2 þ mobilization, FAAH expression is subject to long-term regulation, for example, by estrogens. A putative membrane protein playing a crucial role in regulating the distribution of all endocannabinoids between the intracellular and extracellular milieu, and subsequently their capability to interact with cannabinoid receptors or with degrading enzymes, respectively, is the endocannabinoid membrane transporter (EMT), which is as yet uncharacterised. Although the conclusive word on the actual existence of the EMT will be set only when this protein is cloned, several indirect pieces of evidence 17 suggest that endocannabinoid transport across the cell membrane is due to a specific process and not to simple passive diffusion. Cannabinoid CB 1 receptors, and endocannabinoids to activate them, have been detected in all the brain and peripheral tissues involved in the control of energy intake, processing and storage, including the hypothalamus, the nucleus accumbens, the vagus nerve and the nodose ganglion, myenteric neurons and epithelial cells of the gastrointestinal tract, the adypocytes and the liver. 18 Thus, the body distribution of the endocannabinoid system is fully consistent with its possible role in the control of energy homeostasis.
Evolution of the role of endocannabinoids in ingesting behaviours
As mentioned above, cannabinoid receptor orthologs have been identified in most vertebrate phyla and in a chordate species, the sea squirt C. intestinalis. 4 However, physiologically relevant levels of anandamide and 2-AG have been found also in less evolved organisms, starting with the coelenterate Hydra vulgaris, but also in anellids, echinoderms and molluscs, although not in insects. 4 Interestingly, in H. vulgaris, the first animal to have evolved a neuronal network, anandamide inhibits a typical feeding response, that is it reduces the time during which the mouth remains open following exposure to glutathione, a chemical stimulus that mimics exposure to prey. This effect was due to the anticipation of the mouth closing time, and was blocked by the selective CB 1 antagonist rimonabant (SR141716A), for which specific binding sites, with high affinity also for anandamide, were found in this primitive organism. 19 The inhibitory effect of anandamide was postulated to be due to Figure 1 The endocannabinoids to date.
Endogenous cannabinoids in the brain and peripheral tissues I Matias et al inhibition of GABAergic neurotransmission, which appears to retard mouth closure in H. vulgaris.
In the chordate C. intestinalis, high levels of endocannabinoids have been found in cerebral ganglia, where specific binding sites for cannabinoid agonists also exist. These sites may be the same protein encoded by the CB 1 /CB 2 receptor gene ortholog found in this organism, since this protein contains all the amino acids necessary for the binding to these agonists. 4 Interestingly, one such agonist, HU-210, retards, in a way antagonised by two CB 1 and CB 2 receptor selective antagonists, the reopening time of C. intestinalis buccal siphon after mechanical stimulation-induced mouth closure. 20 Therefore, it is possible that the endocannabinoid system controls also the neuronal mechanisms regulating the feeding behaviour of sea squirts. Endocannabinoids and cannabinoid receptor orthologs have been found also in non-mammalian vertebrates, 4 and also in this case they appear to be involved in the control of feeding behaviour, although seemingly in a rather different way from invertebrates. In the fish Carassius auratus, anandamide exerts a biphasic effect on food intake, and conversely, food deprivation causes an enhancement of anandamide levels in the brain. 21 In the songbird, zebra finch, increased 2-AG levels in the brain are observed following food deprivation, and appear to concur at inhibiting neural processes involved in new song learning via the CB 1 ortholog previously cloned in this bird. 22 These data suggest that endocannabinoids in birds and fish, like in mammals, where their levels also increase after short periods of food deprivation (see below), behave as orexigenic mediators. Such a function, at least in mammals, has now been confirmed by strong experimental evidence, and is summarized below. 
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Regulation of endocannabinoid levels by factors involved in food-intake and energy balance
As mentioned above, the enzymes catalysing the biosynthesis and degradation of anandamide and 2-AG are subject to regulation, at the level both of the activity and the expression, by mediators (neurotransmitters, neuropeptides, hormones, etc.) involved in several physiological and pathological conditions. This results in changes of the levels of the two endocannabinoids, which in turn regulate the levels and action of other (regulatory cascades) or the same (feedback regulation) mediators, via a variety of mechanisms which include, among other things, modulation of neurotransmitter release. 11 Some of the major 'players' in the control of food intake and energy balance also control endocannabinoid levels, and the first example of such regulatory events was provided by the finding that leptin, a key controller of hypothalamic of anorexic and orexigenic mediators, could significantly reduce the levels of anandamide and 2-AG in the rat hypothalamus. 23 This effect, at least for 2-AG, was due to the inhibition of the formation of biosynthetic precursors, and was observed also in ob/ob mice, which lack the capability of producing leptin, but not its receptor, and whose basal hypothalamic content in endocannabinoids is subsequently higher than that of wild-type mice. Higher endocannabinoid levels were also found in db/db mice and Zucker rats, which instead are characterized by impaired leptin receptors, thus substantiating the tonic inhibition by leptin on endocannabinoid levels. 23 Interestingly, leptin decreases endocannabinoid levels also in human T-lymphocytes, 24 whereas in the uterus of ob/ob mice higher amounts of endocannabinoids are again observed. 25 In both cases, the inhibitory effect of leptin on anandamide is due to upregulation of FAAH expression, which, in the case of the human, but not murine, enzyme is caused by the activation, through STAT3, of a cAMP response element-like binding site on the Faah gene promoter. On the other hand, the higher 2-AG levels observed in the uterus of ob/ob mice are due to both increased DAGL activity and decreased MAGL activity, 25 thus suggesting that the tonic inhibitory effect of leptin on this endocannabinoid is due to regulation of both biosynthetic and degradative enzymes. Interestingly, recent findings suggest that endocannabinoids may feed-back positively on leptin production from adipocytes, since CB 1 receptordeficient mice contain less circulating leptin than wild-type mice. 26 Another important signal involved in food intake is ghrelin, released into the bloodstream from the stomach during food deprivation in order to signal to the hypothalamus the need for energy intake. Unlike leptin, ghrelin seems to upregulate hypothalamic endocannabinoid levels since blockade of CB 1 receptors with rimonabant was found to strongly reduce the orexigenic action caused by the hormone when injected into the hypothalamus. 27 Interestingly, rimonabant was also found to reduce the circulating levels of ghrelin in both fasted and fed rats, 28 indicating also in this case the existence of a positive feed-back loop by endocannabinoids on ghrelin production/release. The opposing regulatory effects of leptin and ghrelin on endocannabinoid levels probably provide the molecular basis for the observation that the hypothalamic concentrations of the two CB 1 ligands change dramatically during the different phases of food ingestion, 29 by being lowest during feeding, when the levels of leptin and ghrelin are highest and lowest, respectively, and by being highest during fasting, when the levels of the two hormones are lowest and highest, respectively. However, external factors involved in ingesting behaviours also contribute to determining brain and peripheral endocannabinoid levels, and in particular: (1) the incentive value of food, and (2) its polyunsaturated fatty acid (PUFA) content. In fact, while in order to observe an inhibition of food intake with rimonabant a short period of food deprivation seems to be required in normal rodents, inhibition of palatable food intake is observed also in nonfasted animals. 30 This points to an active role of endocannabinoids in the reinforcement of motivation to consume palatable food. This role is suggested also by the fact that endocannabinoid levels are highest after food deprivation not only in the rat hypothalamus but also in the limbic forebrain, 29 and possibly in the nucleus accumbens, which contributes to translating motivation to eat into action. Furthermore, it has been suggested that the amount and PUFA content of the food consumed can directly influence the levels of the endocannabinoids, possibly by influencing the brain amounts of their phospholipid precursors (Figure 2) . In particular, foods relatively rich in o6 PUFAs, such as in many 'high-fat diets', can significantly enhance the levels of anandamide 31 and 2-AG. 32 On the other hand, as opposed to short-term food deprivation, long-term semistarvation reduces the hypothalamic levels of 2-AG in adult mice, 33 and of anandamide in pups from undernourished rat dams. 34 
Conclusions
A major role of the endocannabinoid system in the control of energy balance can be suggested based on the observation that: (1) even in primitive forms of life endocannabinoids regulate feeding behaviours; (2) in vertebrates and mammals, brain endocannabinoid levels are increased following shortterm food deprivation; (3) two key hormones controlling food intake, leptin and ghrelin, also regulate endocannabinoid levels in seemingly opposing ways, and might be under the positive control of CB 1 receptors; (4) two, possibly related, external factors influencing food-intake, that is palatability and high fat content of the diet, also affect endocannabinoid signalling in the CNS. It will be interesting to confirm the existence of regulatory pathways similar to the ones discussed here also in humans. In this direction, Endogenous cannabinoids in the brain and peripheral tissues I Matias et al data from our laboratory indicate that the blood levels of endocannabinoids in anorexic women are significantly higher than in healthy women, and inversely correlated with blood leptin levels. 35 Furthermore, obese women with binge eating disorder, despite the very high levels of leptin, also possess higher blood endocannabinoid levels, which in this case are positively correlated with body fat mass, thus suggesting that one type of control on the endocannabinoid system may prevail over another during some eating disorders. 35 Indeed, the picture of a general hyperactivity of the endocannabinoid system during obesity, at both the central and peripheral levels, is emerging from recent studies. 36 Data from both animal studies and phase III clinical trials with rimonabant (see other articles in this issue), indicate that these and other regulatory effects occur also in peripheral tissues, particularly in adipocytes, and that the endocannabinoid system may play an important role not only in energy intake but also in lipid metabolism and accumulation, 9, 26 in both animals and humans. 37 
